TN2011000291A1 - Purine compounds - Google Patents

Purine compounds

Info

Publication number
TN2011000291A1
TN2011000291A1 TN2011000291A TN2011000291A TN2011000291A1 TN 2011000291 A1 TN2011000291 A1 TN 2011000291A1 TN 2011000291 A TN2011000291 A TN 2011000291A TN 2011000291 A TN2011000291 A TN 2011000291A TN 2011000291 A1 TN2011000291 A1 TN 2011000291A1
Authority
TN
Tunisia
Prior art keywords
purine compounds
purine
compounds
pain
compound
Prior art date
Application number
TN2011000291A
Other languages
English (en)
French (fr)
Inventor
Peter Charles Astles
Rossella Guidetti
Sean Patrick Hollinshead
Michael Wade Tidwell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TN2011000291A1 publication Critical patent/TN2011000291A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TN2011000291A 2008-12-18 2011-06-09 Purine compounds TN2011000291A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13858908P 2008-12-18 2008-12-18
PCT/US2009/067249 WO2010080306A1 (en) 2008-12-18 2009-12-09 Purine compounds

Publications (1)

Publication Number Publication Date
TN2011000291A1 true TN2011000291A1 (en) 2012-12-17

Family

ID=41719189

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000291A TN2011000291A1 (en) 2008-12-18 2011-06-09 Purine compounds

Country Status (29)

Country Link
US (1) US8252798B2 (https=)
EP (1) EP2379555B1 (https=)
JP (1) JP5559812B2 (https=)
KR (1) KR101319630B1 (https=)
CN (1) CN102256977B (https=)
AR (1) AR075104A1 (https=)
AU (1) AU2009335997B2 (https=)
BR (1) BRPI0923195A2 (https=)
CA (1) CA2746740C (https=)
CL (1) CL2011001464A1 (https=)
CO (1) CO6390101A2 (https=)
CR (1) CR20110340A (https=)
DO (1) DOP2011000196A (https=)
EA (1) EA018386B1 (https=)
EC (1) ECSP11011151A (https=)
ES (1) ES2536880T3 (https=)
HN (1) HN2011001700A (https=)
IL (1) IL213167A (https=)
MA (1) MA32904B1 (https=)
MX (1) MX2011006442A (https=)
NZ (1) NZ593088A (https=)
PA (1) PA8851501A1 (https=)
PE (1) PE20110999A1 (https=)
SG (1) SG172253A1 (https=)
TN (1) TN2011000291A1 (https=)
TW (1) TWI376378B (https=)
UA (1) UA104010C2 (https=)
WO (1) WO2010080306A1 (https=)
ZA (1) ZA201103943B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2665277T3 (es) * 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
CA2770866C (en) 2009-08-28 2017-10-10 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CA2793024A1 (en) * 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
US8710063B2 (en) 2010-03-31 2014-04-29 Eli Lilly And Company Purine compounds used as CB2 agonists
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
MX2013003019A (es) 2010-09-15 2013-05-28 Hoffmann La Roche Compuestos de azabenzotiazol, composiciones y metodos de uso.
MX2013005445A (es) 2010-11-19 2013-07-29 Hoffmann La Roche Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
US9458136B2 (en) 2011-02-25 2016-10-04 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
JP2014526538A (ja) * 2011-09-20 2014-10-06 エフ.ホフマン−ラ ロシュ アーゲー イミダゾピリジン化合物、組成物及び使用方法
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
PE20151140A1 (es) * 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2014177527A1 (en) * 2013-05-02 2014-11-06 F. Hoffmann-La Roche Ag Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017052394A1 (en) * 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
WO2017181317A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2018137176A1 (en) * 2017-01-25 2018-08-02 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2017184412A1 (en) 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis
CA3036382A1 (en) * 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
EP3621619B1 (en) 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
CN118946565A (zh) * 2022-07-21 2024-11-12 长春金赛药业有限责任公司 取代的稠环大麻素受体化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
AU2002336462A1 (en) 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2005067546A2 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CN101044143A (zh) * 2004-10-22 2007-09-26 辉瑞产品公司 制备嘌呤化合物的方法
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
EA024006B1 (ru) * 2006-02-02 2016-08-31 Миллениум Фармасьютикалз, Инк. Ингибиторы е1 активирующих ферментов
WO2011066211A1 (en) * 2009-11-24 2011-06-03 Glaxosmithkline Llc Azabenzimidazoles as fatty acid synthase inhibitors
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor

Also Published As

Publication number Publication date
WO2010080306A1 (en) 2010-07-15
ECSP11011151A (es) 2011-07-29
SG172253A1 (en) 2011-07-28
TW201024296A (en) 2010-07-01
EA018386B1 (ru) 2013-07-30
BRPI0923195A2 (pt) 2016-02-16
CA2746740C (en) 2014-01-14
TWI376378B (en) 2012-11-11
PE20110999A1 (es) 2012-01-16
NZ593088A (en) 2012-12-21
IL213167A0 (en) 2011-07-31
CO6390101A2 (es) 2012-02-29
CN102256977A (zh) 2011-11-23
US20100160288A1 (en) 2010-06-24
PA8851501A1 (es) 2010-07-27
EA201170832A1 (ru) 2011-12-30
EP2379555A1 (en) 2011-10-26
UA104010C2 (en) 2013-12-25
KR20110084459A (ko) 2011-07-22
CN102256977B (zh) 2014-04-16
ES2536880T3 (es) 2015-05-29
CA2746740A1 (en) 2010-07-15
ZA201103943B (en) 2012-11-28
AR075104A1 (es) 2011-03-09
MA32904B1 (fr) 2011-12-01
EP2379555B1 (en) 2015-02-25
MX2011006442A (es) 2011-07-19
AU2009335997A1 (en) 2011-06-23
IL213167A (en) 2013-11-28
DOP2011000196A (es) 2011-10-31
JP5559812B2 (ja) 2014-07-23
US8252798B2 (en) 2012-08-28
KR101319630B1 (ko) 2013-10-17
HN2011001700A (es) 2013-05-06
AU2009335997B2 (en) 2012-05-10
CL2011001464A1 (es) 2012-01-20
JP2012512873A (ja) 2012-06-07
CR20110340A (es) 2011-09-16

Similar Documents

Publication Publication Date Title
TN2011000291A1 (en) Purine compounds
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
SI1853602T1 (sl) Kemične spojine
PL1853588T3 (pl) Związki chemiczne
JO2892B1 (en) CYP inhibitors 17
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
GEP20146125B (en) Aminopyrimidines as syk inhibitors
HUE043569T2 (hu) Vegyületek rák kezelésére
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2012004420A (es) Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.
UY31065A1 (es) Heterociclos ciclicos
MX2012004780A (es) Inhibidores de akt.
SI2117525T1 (sl) Uporaba 1-fenil-3-dimetilamino-propanskih spojin za terapijo nevropatske bolečine
MY160392A (en) Triptolide prodrugs
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
IL209360A (en) Medications containing pm00104 for the treatment of multiple myeloma
EA201270728A1 (ru) Пуриновые соединения
PL2331092T3 (pl) Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
DE602007007934D1 (en) Imidazoazephinonverbindungen
MX2012007426A (es) Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos.
MX2012007097A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
JO2979B1 (en) Cyclopropyl compounds
MX2011011180A (es) Compuestos que tienen efecto fisiologico.